Close Menu

Geisinger Health System

A number of labs and informatics firms are using test data to help guide the response to the virus in a spirit similar to that of initiatives like Lab 2.0.

The firm looks to win new customers among US providers while also partnering with IVD companies to embed its lab data analysis tools in their instruments.

The firm said the clearance authorizes use of its smartphone-based albumin-to-creatinine ratio test by healthcare professionals at the point of care.

Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.

The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.

At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.

The firm said that it anticipates using the funds to scale operations in the US and to continue rolling out its service in the UK.

Over several months, members of the Coalition to Improve Diagnosis identified initial obstacles they believe impede diagnostic accuracy.

The knowledgebase will facilitate the documenting of evidence and implementation of diagnostics-driven population health projects.

At the recent CVS, the two large health systems described introducing Cepheid platforms for flu testing across rural and satellite locations.

Pages